Hamouda W E, Roshdy W, Teema M
Department of Radiation-oncology, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Gulf J Oncolog. 2007 Jan;1(1):35-41.
To compare a single 8 Gy fraction with conventional regimen of 40 Gy in 20 fractions as a palliative treatment to patients with bone metastasis and reducing the treatment burden for both the patients and Hospital Staff.
One hundred and seven patients with painful localized bone metastases requiring palliative radiotherapy were entered into a prospective randomized trial comparing 8 Gy single fraction (SF group) with 40 Gy in 20 fractions, five fractions/week (CF group). The primary tumor was in the breast in (48.1%) of the patients, in the lung in (20.6%) in the prostate in (17.6%), and in other sites in (13.7%). Bone metastases were located in the spine (42.2%), pelvis (29.4%) limbs (21.6%), and other sites (6.8%). Pain relief was measured by visual analogue scale (VAS) and also by analgesic requirement. Evaluation was performed before and at 2 weeks then every 4 weeks for 24 weeks after treatment. A total of 102 patients were evaluable for response; 50 in the SF group and 52 in the CF group.
There were no significant diferences in the frequency or duration of pain relief between the two study groups. In both groups, the maximum benefit was achieved at 8 weeks after treatment; 41 patients (82%) in SF group and (44%) of those in the CF group. The frequency of pain by > or =50% on VAS. Complete pain relief was reported in (44%) of those in the CF group. The frequency of pain relief did not differ between the two groups with respect to the primary tumor, the metastatic sites, and the performance status, but for patients as a whole, there was a significantly lower response rate for lung cancer patients (61.9%) in comparision to patients with breast (91.8%) and prostate (100%) cancer. The median duration of pain relief was 12 weeks in the SF group and 13.5 weeks in CF group. During follow-up, 7 patients (6 in SF group and one in CF group) had their bone metastases re-irradiated. Six of these re-irradiated patients also achieved pain relief.
This study indicates that a single fraction of 8 Gy is as effective as 40 Gy in 20 fractions for the palliation of painful bone metastases. Single fraction schedule may be preferred for patient convenience and an option for re-treatment in the case of recurrent pain.
比较单次8 Gy分割放疗与传统的20次分割共40 Gy放疗方案对骨转移患者的姑息治疗效果,并减轻患者和医院工作人员的治疗负担。
107例需要姑息性放疗的局部疼痛性骨转移患者进入一项前瞻性随机试验,比较单次8 Gy分割放疗组(SF组)与20次分割共40 Gy、每周5次分割放疗组(CF组)。48.1%的患者原发肿瘤位于乳腺,20.6%位于肺,17.6%位于前列腺,13.7%位于其他部位。骨转移位于脊柱(42.2%)、骨盆(29.4%)、四肢(21.6%)和其他部位(6.8%)。通过视觉模拟量表(VAS)和镇痛药需求来衡量疼痛缓解情况。在治疗前、治疗后2周进行评估,然后在治疗后24周内每4周评估一次。共有102例患者可评估疗效;SF组50例,CF组52例。
两组在疼痛缓解的频率或持续时间上无显著差异。两组均在治疗后8周达到最大疗效;SF组41例(82%),CF组44%。VAS评分疼痛减轻≥50%的频率。CF组44%的患者报告完全缓解疼痛。两组在原发肿瘤、转移部位和体能状态方面的疼痛缓解频率无差异,但总体而言,肺癌患者的缓解率(61.9%)显著低于乳腺癌(91.8%)和前列腺癌(100%)患者。SF组疼痛缓解的中位持续时间为12周,CF组为13.5周。随访期间,7例患者(SF组6例,CF组1例)对骨转移灶进行了再次放疗。这些再次放疗的患者中有6例也实现了疼痛缓解。
本研究表明,单次8 Gy分割放疗在缓解疼痛性骨转移方面与20次分割共40 Gy放疗同样有效。单次分割方案可能因方便患者而更受青睐,并且在复发性疼痛的情况下是再次治疗的一个选择。